At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Itacitinib +1 moredrug
Likely dose
Ruxolitinib 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
In Brief
A Phase 2 clinical trial evaluating Itacitinib and Ruxolitinib for MPN (Myeloproliferative Neoplasms). Completed, enrolled 23 participants across 26 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in participants with myelofibrosis (MF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMPN (Myeloproliferative Neoplasms)
CountriesAustria, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJan 2018
Primary CompletionMar 2020
Study CompletionJun 2021
TodayJul 2026
First PostedMay 9, 2017
Enrollment StartJan 26, 2018
Primary CompletionMar 14, 2020
Study CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.1 years ago
Interventions
Itacitinibdrug
Itacitinib self-administered orally once daily .
Ruxolitinibdrug
Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.